GPR35; ADRA2C; ADRA2A; DRD4; | |
NPSR1; CXCR1; NMUR2; | |
RECQL; PLA2G1B; TDP1; BLM; APOBEC3G; CTDSP1; PIK3CG; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; AKR1B10; ALDH1A1; ALOX12; NOX4; USP2; PYGL; APEX1; POLB; | |
ACHE; GAA; | |
TOP2A; | |
NEK6; AKT1; MET; CAMK2B; INSR; CSNK2A1; DAPK1; SYK; NEK2; FLT3; MYLK; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; EGFR; PIM1; NUAK1; ALK; FYN; AXL; KDR; PKN1; | |
CA14; CA5A; CA3; CA7; CA1; CA12; CA9; CA4; CA6; CA2; | |
AR; | |
ESRRA; | |
KDM4E; | |
MAOA; ALOX5; TYR; XDH; | |
MMP13; MMP12; MMP3; MMP2; MMP9; | |
BACE1; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
ABCC1; ABCG2; | |
LMNA; MAPT; THPO; APP; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | APOBEC3G | DNA dC->dU-editing enzyme APOBEC-3G | Q9HC16 | CHEMBL1741217 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | PIK3CG | PI3-kinase p110-gamma subunit | P48736 | CHEMBL3267 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | MYLK | Myosin light chain kinase, smooth muscle | Q15746 | CHEMBL2428 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.844E-12 | 5.656E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.094E-12 | 1.101E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 2.893E-11 | 6.300E-09 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, GSK3B, MAPK1, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, SYK |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.496E-11 | 1.098E-08 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 8.331E-11 | 1.591E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, SRC |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.313E-10 | 2.325E-08 | EGFR, FYN, IGF1R, INSR, KDR, PTK2, SRC, SYK |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.588E-10 | 5.661E-08 | ADRA2A, ADRA2C, AKT1, AXL, FYN, MAPK1, PIK3CG, PIK3R1, SRC, SYK |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 5.333E-10 | 8.009E-08 | AXL, EGFR, FYN, INSR, MET, NOX4, PIK3CG, PIK3R1, PTK2, SRC, THPO |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 7.625E-10 | 1.085E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.009E-09 | 1.399E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.544E-09 | 2.002E-07 | APOBEC3G, AR, BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, ESRRA, GLO1, L3MBTL1, MMP12, MMP13, MMP2, MMP3, MMP9, TP53 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.861E-09 | 2.356E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.005E-09 | 3.713E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.134E-08 | 1.280E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.875E-08 | 2.033E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, SYK |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 9.412E-08 | 9.149E-06 | EGFR, INSR, KDR, SYK |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.932E-07 | 1.783E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.278E-07 | 2.059E-05 | ADRA2A, AURKB, CA2, CA7, EGFR, FYN, HIF1A, KDR, MAPK1, NEK2, NPSR1, PLA2G1B, SRC, SYK |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.596E-07 | 3.059E-05 | AURKB, CA2, CA7, EGFR, HIF1A, MAPK1, NEK2, NPSR1, PLA2G1B, SYK |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.652E-07 | 3.094E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 4.193E-07 | 3.498E-05 | AXL, FYN, IGF1R, INSR, PIK3R1 |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 4.662E-07 | 3.860E-05 | ADRA2C, AKT1, ALOX12, APP, AR, AXL, CA2, CAMK2B, CDK1, CTDSP1, CYP1B1, EGFR, ESRRA, FYN, GSK3B, HIF1A, INSR, KDR, L3MBTL1, MAPT, PIK3R1, PIM1, PTK2, SRC, STAT6, SYK, THPO, XDH |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 5.949E-07 | 4.780E-05 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 7.021E-07 | 5.539E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 8.690E-07 | 6.734E-05 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 9.620E-07 | 7.428E-05 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 9.744E-07 | 7.498E-05 | ALK, CDK1, DRD4, INSR, MAPK1, PKN1, PLA2G1B, SYK |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.321E-06 | 1.002E-04 | ALOX12, ALOX15, ALOX5, HPGD |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.461E-06 | 1.090E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.578E-06 | 1.165E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 2.332E-06 | 1.670E-04 | AXL, FYN, KDR, PIK3R1, PTK2, SRC |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 2.530E-06 | 1.783E-04 | MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.911E-06 | 2.019E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0032502; developmental process | GO:0007568; aging | 4.053E-06 | 2.741E-04 | AKT1, APEX1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 4.600E-06 | 3.063E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, APOBEC3G, BLM, CAMK2B, FLT3, HPGD, MAPT, NFKB1, PYGL, TOP2A, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 4.860E-06 | 3.207E-04 | ADRA2A, AHR, AKT1, APEX1, APP, AR, AURKB, BLM, CDK1, CSNK2A1, CTDSP1, DAPK1, DRD4, ESRRA, FYN, GSK3B, HIF1A, IGF1R, L3MBTL1, MAPT, MET, MMP12, MMP3, MMP9, NFKB1, PIK3CG, PKN1, SRC, STAT6, TP53, USP2, XDH |
CC | GO:0044464; cell part | GO:0005829; cytosol | 5.814E-06 | 3.757E-04 | AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APOBEC3G, APP, AR, AURKB, BLM, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, FLT3, FYN, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, LMNA, MAPK1, MAPT, MYLK, NEK2, NEK6, NFKB1, PIK3CG, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PYGL, SRC, STAT6, SYK, TP53, TYR, XDH |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 6.608E-06 | 4.159E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 8.088E-06 | 5.017E-04 | ADRA2A, ADRA2C, DRD4 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.101E-05 | 6.675E-04 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.208E-05 | 7.229E-04 | APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.208E-05 | 7.229E-04 | BLM, RECQL, TP53 |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.868E-05 | 1.062E-03 | AKT1, AR, DAPK1, FYN, LMNA, SRC |
BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 1.988E-05 | 1.119E-03 | ACHE, AKR1B10, AKT1, ALDH1A1, APOBEC3G, AURKB, BACE1, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, GAA, GSK3B, HSD17B10, MAOA, PLA2G1B, PYGL, TP53, USP2, XDH |
MF | Unclassified; | GO:0032403; protein complex binding | 2.017E-05 | 1.129E-03 | ACHE, ADRA2A, APEX1, EGFR, FLT3, FYN, IGF1R, INSR, KDR, MMP12, MMP13, MMP9, PIK3R1, SRC, SYK |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 2.293E-05 | 1.258E-03 | ADRA2A, AKT1, HIF1A, INSR, NOX4, PIK3R1, PYGL |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 2.355E-05 | 1.282E-03 | IGF1R, INSR, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.505E-05 | 1.357E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 2.699E-05 | 1.441E-03 | EGFR, FYN, MET, PIK3CG, PIK3R1 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 2.714E-05 | 1.441E-03 | APP, BACE1, EGFR, FYN, INSR, KDR, MAPK1, SRC, STAT6 |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 2.816E-05 | 1.463E-03 | EGFR, NMUR2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.816E-05 | 1.463E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.816E-05 | 1.463E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.816E-05 | 1.463E-03 | ALOX12, ALOX15 |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 3.122E-05 | 1.607E-03 | AKT1, HIF1A, INSR, NFKB1, SRC |
MF | GO:0005488; binding | GO:0002039; p53 binding | 3.594E-05 | 1.833E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 3.666E-05 | 1.861E-03 | CA3, CDK1, FYN, HPGD, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 3.939E-05 | 1.985E-03 | ADRA2A, ADRA2C, FLT3, FYN, SRC, SYK, TP53 |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 4.051E-05 | 2.019E-03 | CYP19A1, HSD17B1, HSD17B2 |
CC | GO:0044464; cell part | GO:0031234; extrinsic component of cytoplasmic side of plasma membrane | 4.120E-05 | 2.044E-03 | ALOX15, FYN, PTK2, SRC, SYK |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 4.394E-05 | 2.157E-03 | AKT1, AURKB, BLM, CSNK2A1, L3MBTL1, NUAK1, TP53 |
BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 4.704E-05 | 2.291E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 4.965E-05 | 2.397E-03 | ADRA2A, AKT1, APP, CDK1, DAPK1, GSK3B, MAPT, PTK2, SRC, XDH |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 5.036E-05 | 2.426E-03 | AKT1, APP, EGFR, FYN, INSR, KDR, NOX4, SRC |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 5.349E-05 | 2.560E-03 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
BP | GO:0022610; biological adhesion | GO:0033628; regulation of cell adhesion mediated by integrin | 6.012E-05 | 2.840E-03 | CYP1B1, PIK3CG, PTK2, SYK |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 6.236E-05 | 2.939E-03 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, HPGD |
BP | GO:0032501; multicellular organismal process | GO:0045780; positive regulation of bone resorption | 6.395E-05 | 2.995E-03 | CA2, EGFR, SYK |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 6.444E-05 | 3.011E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0038096; Fc-gamma receptor signaling pathway involved in phagocytosis | 6.939E-05 | 3.194E-03 | FYN, MAPK1, PIK3R1, PTK2, SRC, SYK |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 6.926E-05 | 3.194E-03 | ADRA2A, ADRA2C, AHR, AXL, EGFR, HIF1A, NFKB1, PIK3R1, TOP2A, TP53, TYR |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 7.264E-05 | 3.330E-03 | AKR1B1, AKT1, AR, EGFR, SRC |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.418E-05 | 3.749E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 8.418E-05 | 3.749E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 8.418E-05 | 3.749E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 8.418E-05 | 3.749E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 8.418E-05 | 3.749E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 8.785E-05 | 3.888E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 8.946E-05 | 3.936E-03 | ALOX15, APP, EGFR, KDR, NOX4, SRC, THPO |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 9.483E-05 | 4.122E-03 | AURKB, MAPK1, NEK2 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 9.483E-05 | 4.122E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 9.483E-05 | 4.122E-03 | AURKB, CDK1, PKN1 |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 9.537E-05 | 4.137E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MMP9, NOX4, SRC, TOP2A, TP53, XDH |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 9.566E-05 | 4.141E-03 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKB, BLM, CAMK2B, CDK1, CSNK2A1, CTDSP1, ESRRA, GSK3B, HIF1A, HPGD, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NUAK1, PIM1, PKN1, POLB, RECQL, SRC, STAT6, TOP2A, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 9.603E-05 | 4.149E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0032928; regulation of superoxide anion generation | 1.134E-04 | 4.793E-03 | EGFR, MAPT, SYK |
BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 1.190E-04 | 4.983E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B, SYK |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.255E-04 | 5.215E-03 | CA2, CA7, FYN, KDR, NPSR1, PLA2G1B, SRC |
BP | GO:0050896; response to stimulus | GO:0071320; cellular response to cAMP | 1.454E-04 | 5.941E-03 | APEX1, APP, NOX4, PIK3CG |
BP | GO:0008152; metabolic process | GO:0010605; negative regulation of macromolecule metabolic process | 1.470E-04 | 5.986E-03 | AHR, AKT1, APEX1, APP, AR, AURKB, BLM, CDK1, CSNK2A1, CTDSP1, DAPK1, EGFR, ESRRA, FYN, GSK3B, HIF1A, IGF1R, KDR, L3MBTL1, MAPT, MMP12, MMP9, NFKB1, PKN1, SRC, STAT6, TP53, USP2, XDH |
MF | GO:0003824; catalytic activity | GO:0004715; non-membrane spanning protein tyrosine kinase activity | 1.572E-04 | 6.257E-03 | FYN, PTK2, SRC, SYK |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 1.678E-04 | 6.559E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 1.678E-04 | 6.559E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.678E-04 | 6.559E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 1.678E-04 | 6.559E-03 | APP, INSR |
MF | GO:0005488; binding | GO:0005497; androgen binding | 1.678E-04 | 6.559E-03 | ALDH1A1, AR |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.826E-04 | 7.052E-03 | CYP1A1, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0046854; phosphatidylinositol phosphorylation | 1.880E-04 | 7.219E-03 | EGFR, FYN, MET, PIK3CG, PIK3R1 |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 2.036E-04 | 7.698E-03 | ALOX15, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.106E-04 | 7.841E-03 | HPGD, MMP2, MMP9 |
BP | GO:0008152; metabolic process | GO:0050995; negative regulation of lipid catabolic process | 2.106E-04 | 7.841E-03 | ADRA2A, AKT1, PIK3CG |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 2.262E-04 | 8.378E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 2.266E-04 | 8.378E-03 | AKT1, ALOX12, ALOX15, FYN, GSK3B, KDR, PIK3R1, SRC, SYK |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 2.367E-04 | 8.705E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 2.413E-04 | 8.831E-03 | DRD4, NMUR2, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.413E-04 | 8.831E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032502; developmental process | GO:0048638; regulation of developmental growth | 2.609E-04 | 9.453E-03 | AKT1, APP, AR, CDK1, INSR, MAPT, PIM1, PTK2 |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 2.636E-04 | 9.517E-03 | ADRA2A, AKT1, CDK1, DAPK1, GSK3B, HIF1A, INSR, KDR, PTK2 |
BP | GO:0007610; behavior | GO:0007611; learning or memory | 2.655E-04 | 9.555E-03 | APP, EGFR, FYN, HIF1A, INSR, MAPK1, MAPT |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 2.655E-04 | 9.555E-03 | ACHE, EGFR, HIF1A, MMP12, PLA2G1B, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0002679; respiratory burst involved in defense response | 2.787E-04 | 9.819E-03 | MPO, PIK3CG |
BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.787E-04 | 9.819E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 2.787E-04 | 9.819E-03 | BLM, RECQL |
MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 2.787E-04 | 9.819E-03 | ADRA2A, DRD4 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.821E-04 | 9.892E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.486E-20 | 1.898E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.536E-14 | 1.347E-11 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 8.248E-14 | 3.665E-11 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, FLT3, FYN, GSK3B, IGF1R, INSR, KDR, MAPK1, MET, MYLK, NEK2, NEK6, NUAK1, PIK3CG, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TOP2A, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.038E-13 | 7.397E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.582E-19 | 2.942E-17 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.385E-13 | 1.288E-11 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; MMP9; PTK2; EGFR; PIK3CG; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.986E-11 | 1.231E-09 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PIK3CG; PTK2; IGF1R; AR; AKT1; MAPK1; MET; TP53 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.048E-11 | 1.387E-09 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1; PIK3CG; IGF1R |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 3.728E-11 | 1.387E-09 | GSK3B; SRC; PIK3R1; PTK2; EGFR; PIK3CG; MYLK; IGF1R; KDR; AKT1; MAPK1; FYN; MET |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.317E-10 | 4.310E-09 | GSK3B; SYK; INSR; PIK3R1; PTK2; EGFR; NFKB1; PIK3CG; IGF1R; KDR; AKT1; MAPK1; PKN1; TP53; MET |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.958E-11 | 1.847E-09 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR; PIK3CG |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.333E-10 | 3.098E-09 | CAMK2B; INSR; AKT1; MAPK1; PIK3R1; HIF1A; EGFR; NFKB1; PIK3CG; IGF1R |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.685E-10 | 3.483E-09 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.487E-09 | 2.177E-08 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; EGFR; PIK3CG; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 6.566E-10 | 1.110E-08 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; EGFR; PTK2; PIK3CG |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.111E-10 | 2.952E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.056E-09 | 4.060E-08 | AKT1; MAPK1; PIK3R1; TP53; MET; EGFR; PIK3CG; IGF1R |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.326E-09 | 7.354E-08 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.275E-09 | 5.300E-08 | CSNK2A1; SRC; INSR; MAPK1; FYN; MET; EGFR; IGF1R |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.522E-09 | 2.177E-08 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53; EGFR |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.523E-08 | 2.234E-07 | PLA2G1B; INSR; KDR; AKT1; MAPK1; PIK3R1; MET; EGFR; NFKB1; PIK3CG; IGF1R |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.474E-08 | 1.523E-07 | ALK; AKT1; MAPK1; PIK3R1; TP53; EGFR; PIK3CG |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 8.646E-09 | 9.459E-08 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; EGFR; PIK3CG |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.673E-08 | 1.638E-07 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.715E-08 | 2.295E-07 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2; PIK3CG |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.368E-08 | 3.250E-07 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; EGFR; PIK3CG |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.108E-08 | 2.409E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 6.438E-08 | 4.277E-07 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; PIK3CG |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.714E-08 | 3.937E-07 | SYK; CXCR1; INSR; AKT1; MAPK1; FYN; PIK3R1; EGFR; PIK3CG |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.386E-07 | 8.319E-07 | SRC; INSR; KDR; AKT1; MAPK1; PIK3R1; MET; EGFR; PIK3CG; IGF1R |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.047E-08 | 2.409E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.745E-08 | 3.395E-07 | AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1; PIK3CG |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.895E-08 | 1.762E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.666E-07 | 1.340E-06 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; CYP2C9; CYP2C8; AKR1B10; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 8.752E-08 | 5.613E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.640E-08 | 5.977E-07 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.722E-07 | 1.001E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A; PIK3CG |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.962E-07 | 1.073E-06 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.229E-07 | 1.152E-06 | SYK; SRC; AKT1; MAPK1; FYN; PIK3R1; PIK3CG; MYLK |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.962E-07 | 1.073E-06 | ABCC1; AKT1; MAPK1; FYN; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 5.308E-07 | 2.468E-06 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2; PIK3CG |
hsa05162 | Measles_Homo sapiens_hsa05162 | 5.135E-07 | 2.449E-06 | GSK3B; CSNK2A1; AKT1; FYN; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.330E-07 | 2.119E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1; PIK3CG |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.012E-06 | 4.279E-06 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 9.046E-07 | 3.913E-06 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.544E-07 | 2.515E-06 | INSR; AKT1; PIK3R1; TP53; NFKB1; PIK3CG; IGF1R |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.144E-06 | 4.435E-06 | POLB; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.166E-07 | 1.151E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.103E-06 | 4.435E-06 | GSK3B; AKT1; MAPK1; FYN; PIK3R1; NFKB1; PIK3CG |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.713E-06 | 6.011E-06 | CAMK2B; ACHE; AKT1; MAPK1; FYN; PIK3R1; PIK3CG |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.612E-06 | 5.765E-06 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1; PIK3CG |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.515E-06 | 5.527E-06 | GSK3B; INSR; AKT1; PIK3R1; PYGL; NFKB1; PIK3CG |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 2.422E-06 | 8.192E-06 | INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A; PIK3CG; MYLK |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 7.839E-07 | 3.471E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; PIK3CG |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.019E-06 | 2.486E-05 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 5.442E-06 | 1.776E-05 | SYK; AKT1; MAPK1; FYN; PIK3R1; NFKB1; PIK3CG |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.361E-06 | 5.167E-06 | SYK; AKT1; MAPK1; FYN; PIK3R1; PIK3CG |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 5.720E-06 | 1.834E-05 | INSR; AKT1; MAPK1; PIK3R1; EGFR; PIK3CG; IGF1R |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 7.650E-06 | 2.412E-05 | GSK3B; INSR; AKT1; MAPK1; PIK3R1; PYGL; PIK3CG |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.139E-06 | 4.435E-06 | AKT1; MAPK1; PIK3R1; MET; HIF1A; PIK3CG |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.304E-05 | 6.492E-05 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; EGFR; NFKB1 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 1.765E-05 | 5.129E-05 | CAMK2B; SRC; MAPK1; PIK3R1; EGFR; PIK3CG; MYLK |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.040E-06 | 4.299E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.156E-05 | 3.524E-05 | CDK1; AKT1; MAPK1; PIK3R1; PIK3CG; IGF1R |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.074E-06 | 7.143E-06 | AKT1; MAPK1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.374E-05 | 4.123E-05 | AKT1; MAPK1; PIK3R1; HIF1A; EGFR; PIK3CG |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.426E-06 | 1.776E-05 | AKT1; PIK3R1; TP53; NFKB1; PTK2; PIK3CG |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.485E-06 | 5.523E-06 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.330E-05 | 9.109E-05 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.209E-04 | 2.922E-04 | SRC; MAPK1; PIK3R1; PTK2; EGFR; PIK3CG; MYLK |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 9.361E-05 | 2.385E-04 | GSK3B; AKT1; MAPK1; PIK3R1; PIK3CG; IGF1R |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.313E-04 | 3.130E-04 | GSK3B; INSR; AKT1; PIK3R1; NFKB1; PIK3CG |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.681E-04 | 3.908E-04 | THPO; PIM1; AKT1; STAT6; PIK3R1; PIK3CG |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.920E-04 | 6.316E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.075E-04 | 2.690E-04 | CAMK2B; SRC; MMP2; MAPK1; EGFR |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.344E-04 | 5.191E-04 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.789E-04 | 7.919E-04 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1; PIK3CG |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.199E-04 | 6.839E-04 | CAMK2B; SYK; SRC; AKT1; MAPK1; NFKB1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.526E-04 | 3.594E-04 | CAMK2B; SRC; ALOX12; PIK3R1; PIK3CG |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.192E-04 | 2.918E-04 | SYK; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.205E-04 | 4.942E-04 | AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.017E-04 | 4.576E-04 | AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.233E-03 | 4.033E-03 | CXCR1; SRC; KDR; MET; EGFR; IGF1R |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.066E-03 | 3.768E-03 | AKT1; MAPK1; MAPT; TP53; EGFR; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.779E-04 | 1.132E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; NFKB1; PIK3CG |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.503E-03 | 4.477E-03 | CXCR1; THPO; FLT3; KDR; MET; EGFR |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.388E-04 | 9.069E-04 | CAMK2B; AR; CDK1; MAPK1; IGF1R |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.014E-03 | 1.945E-03 | CAMK2B; AKT1; MAPK1; PIK3R1; PIK3CG |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 4.554E-04 | 9.308E-04 | INSR; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.432E-02 | 2.258E-02 | GPR35; NMUR2; ADRA2C; ADRA2A; DRD4 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.147E-05 | 1.348E-04 | SRC; PIK3R1; MET; PTK2; PIK3CG |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.626E-04 | 7.664E-04 | MMP2; PIK3R1; MMP9; PTK2; PIK3CG |
hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 6.707E-04 | 1.300E-03 | SYK; MAPK1; FYN; PIK3R1; PIK3CG |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 6.259E-03 | 1.078E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.433E-05 | 4.230E-05 | AKT1; MAPK1; PIK3R1; HIF1A; PIK3CG |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 5.456E-04 | 1.080E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.968E-05 | 5.632E-05 | INSR; AKT1; PIK3R1; PIK3CG; IGF1R |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 5.080E-04 | 1.016E-03 | GSK3B; MAPK1; FYN; MET; PTK2 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.541E-02 | 2.369E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.738E-05 | 1.008E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.627E-02 | 3.897E-02 | GSK3B; CDK1; TP53 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 2.647E-05 | 7.349E-05 | CXCR1; SRC; MET; EGFR; NFKB1 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.781E-03 | 3.281E-03 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.414E-02 | 3.621E-02 | PLA2G1B; MAPK1; MYLK |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.536E-02 | 2.369E-02 | CAMK2B; AKT1; PYGL |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.781E-03 | 3.281E-03 | PIK3R1; NFKB1; PTK2; PIK3CG |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.232E-02 | 2.009E-02 | SYK; CSNK2A1; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 9.967E-03 | 1.655E-02 | MAPK1; PKN1; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.110E-03 | 2.107E-03 | SRC; CDK1; MAPK1; EGFR |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 6.599E-03 | 1.126E-02 | CAMK2B; CA2; MYLK |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.883E-03 | 1.032E-02 | CA2; CYP3A4; ABCG2 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.984E-04 | 4.555E-04 | INSR; AKT1; PIK3R1; PIK3CG |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 4.597E-03 | 8.144E-03 | SRC; MAPK1; NFKB1 |
hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 3.268E-02 | 4.786E-02 | GSK3B; TP53 |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 3.378E-02 | 4.908E-02 | GAA; PYGL |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.640E-02 | 3.897E-02 | MAOA; NFKB1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.085E-04 | 2.690E-04 | INSR; MAPK1; PIK3R1; PIK3CG |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.347E-02 | 3.548E-02 | CYP3A4; XDH |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.159E-02 | 3.292E-02 | ABCC1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 4.750E-05 | 1.262E-04 | INSR; MAPK1; PIK3R1; PIK3CG |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.609E-03 | 3.022E-03 | AKT1; PIK3R1; PIK3CG |
hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.399E-02 | 2.224E-02 | MAPK1; FYN |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 5.257E-05 | 1.358E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.740E-03 | 1.632E-02 | MAPK1; TP53 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.399E-02 | 2.224E-02 | MAOA; TYR |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 8.477E-03 | 1.433E-02 | MAPK1; EGFR |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.178E-02 | 1.939E-02 | AKR1B10; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.250E-02 | 2.022E-02 | POLB; APEX1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.477E-02 | 2.308E-02 | AKR1B10; AKR1B1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.868E-04 | 9.841E-04 | AKR1B10; GAA; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.193E-03 | 1.076E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.600E-04 | 5.690E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; PIK3CG; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1; PIK3CG |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADRA2C |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | PIK3CG; EGFR; EGFR; KDR; APP |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
NA: NA | Enthesopathy | NA | PIK3CG |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; GSK3B; CSNK2A1; SYK; PIK3CG; CA1; FLT3; FLT3; CA9; MMP2; ACHE; SRC; IGF1R; PTK2; HIF1A; CDK1; MAPK1; MMP9; NFKB1; EGFR; PIM1; TP53; KDR; APP |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; SYK; MMP3; TYR |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; SYK; SYK; MMP12; ADRA2C |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; ACHE; IGF1R; INSR; CDK1; ADRA2C; ADRA2A |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
C00-D49: Neoplasms | Breast cancer | C50 | AR; PIK3CG; FLT3; FLT3; CA9; IGF1R; INSR; CYP19A1; CDK1; EGFR; EGFR; EGFR; KDR; KDR; KDR |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK; EGFR |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; AURKB; TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
NA: NA | Geographic retinal atrophy | NA | APP |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
NA: NA | HIV infections | NA | AHR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PIK3CG; PIK3CG; INSR; NFKB1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; PIK3CG; MMP12 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; PIK3CG; PIK3CG; CA9; INSR; HIF1A; EGFR |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B; SRC |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B; INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; TP53; KDR |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; PIK3CG; FLT3; EGFR |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
C00-D49: Neoplasms | Endometrial cancer | C54.1 | PIK3CG; PIK3CG |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; KDR; KDR |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | PIK3CG; KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT; ACHE; ACHE; ACHE; INSR; ADRA2C; APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; EGFR; EGFR; KDR; KDR; KDR; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; EGFR; KDR |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; PIK3CG; PIK3CG |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
NA: NA | Angioedema | NA | PIK3CG |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
C00-D49: Neoplasms | Melanoma | C43 | EGFR; TYR; KDR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | SYK; INSR |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2; MYLK |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | PIK3CG; CYP2C9 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
C00-D49: Neoplasms | Diffuse large B-cell lymphoma | C83.3 | PIK3CG |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; PIK3CG |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5; MMP12 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; EGFR; EGFR; KDR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK; PIK3CG; PIK3CG |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; SYK; PIK3CG; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; EGFR; TP53; KDR; KDR; KDR; TOP2A |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | PIK3CG; MMP3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |